Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells

Christian Hassager, Susan K. Bonde, Marlys A. Anderson, H. Rink, Thomas C. Spelsberg, B. Lawrence Riggs

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The NH2-terminal cleavage peptide of procalcitonin (N-proCT) recently was reported to be a bone cell mitogen (Burns DM et al., Proc Natl Acad Sci USA 86:9519-9523, 1989). We have investigated the effect of N-proCT on the proliferation of normal human cells that have the phenotype of mature osteoblasts (hOB cells). N-proCT treatment for 24, 48, or 96 h in concentrations from 1 nM to 1 μm did not significantly increase [3H]thymidine uptake (means ranged from -19% to 38% of control, no significant differences) in hOB cells (6-10 cell strains per experiment) plated at four different densities. However, the hOB cells responded significantly to treatment with transforming growth factor β (3 ng/ml), bovine insulin (300 μg/ml), or 30% fetal calf serum, which were included in all experiments as positive controls. The [3H]thymidine uptake data were confirmed in a direct cell count experiment tested at 96 h. Thus our data do not support the hypothesis that N-proCT is a potent mitogen for normal human osteoblasts.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalJournal of Bone and Mineral Research
Volume6
Issue number5
StatePublished - May 1991

Fingerprint

Calcitonin
Osteoblasts
Peptides
Mitogens
Thymidine
Transforming Growth Factors
Burns
Cell Count
Insulin
Phenotype
Bone and Bones
Serum

ASJC Scopus subject areas

  • Surgery

Cite this

Hassager, C., Bonde, S. K., Anderson, M. A., Rink, H., Spelsberg, T. C., & Riggs, B. L. (1991). Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells. Journal of Bone and Mineral Research, 6(5), 489-493.

Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells. / Hassager, Christian; Bonde, Susan K.; Anderson, Marlys A.; Rink, H.; Spelsberg, Thomas C.; Riggs, B. Lawrence.

In: Journal of Bone and Mineral Research, Vol. 6, No. 5, 05.1991, p. 489-493.

Research output: Contribution to journalArticle

Hassager, C, Bonde, SK, Anderson, MA, Rink, H, Spelsberg, TC & Riggs, BL 1991, 'Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells', Journal of Bone and Mineral Research, vol. 6, no. 5, pp. 489-493.
Hassager, Christian ; Bonde, Susan K. ; Anderson, Marlys A. ; Rink, H. ; Spelsberg, Thomas C. ; Riggs, B. Lawrence. / Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells. In: Journal of Bone and Mineral Research. 1991 ; Vol. 6, No. 5. pp. 489-493.
@article{fea733c041894dd48fce20d8c0891535,
title = "Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells",
abstract = "The NH2-terminal cleavage peptide of procalcitonin (N-proCT) recently was reported to be a bone cell mitogen (Burns DM et al., Proc Natl Acad Sci USA 86:9519-9523, 1989). We have investigated the effect of N-proCT on the proliferation of normal human cells that have the phenotype of mature osteoblasts (hOB cells). N-proCT treatment for 24, 48, or 96 h in concentrations from 1 nM to 1 μm did not significantly increase [3H]thymidine uptake (means ranged from -19{\%} to 38{\%} of control, no significant differences) in hOB cells (6-10 cell strains per experiment) plated at four different densities. However, the hOB cells responded significantly to treatment with transforming growth factor β (3 ng/ml), bovine insulin (300 μg/ml), or 30{\%} fetal calf serum, which were included in all experiments as positive controls. The [3H]thymidine uptake data were confirmed in a direct cell count experiment tested at 96 h. Thus our data do not support the hypothesis that N-proCT is a potent mitogen for normal human osteoblasts.",
author = "Christian Hassager and Bonde, {Susan K.} and Anderson, {Marlys A.} and H. Rink and Spelsberg, {Thomas C.} and Riggs, {B. Lawrence}",
year = "1991",
month = "5",
language = "English (US)",
volume = "6",
pages = "489--493",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Procalcitonin NH2-terminal cleavage peptide has no mitogenic effect on normal human osteoblast-like cells

AU - Hassager, Christian

AU - Bonde, Susan K.

AU - Anderson, Marlys A.

AU - Rink, H.

AU - Spelsberg, Thomas C.

AU - Riggs, B. Lawrence

PY - 1991/5

Y1 - 1991/5

N2 - The NH2-terminal cleavage peptide of procalcitonin (N-proCT) recently was reported to be a bone cell mitogen (Burns DM et al., Proc Natl Acad Sci USA 86:9519-9523, 1989). We have investigated the effect of N-proCT on the proliferation of normal human cells that have the phenotype of mature osteoblasts (hOB cells). N-proCT treatment for 24, 48, or 96 h in concentrations from 1 nM to 1 μm did not significantly increase [3H]thymidine uptake (means ranged from -19% to 38% of control, no significant differences) in hOB cells (6-10 cell strains per experiment) plated at four different densities. However, the hOB cells responded significantly to treatment with transforming growth factor β (3 ng/ml), bovine insulin (300 μg/ml), or 30% fetal calf serum, which were included in all experiments as positive controls. The [3H]thymidine uptake data were confirmed in a direct cell count experiment tested at 96 h. Thus our data do not support the hypothesis that N-proCT is a potent mitogen for normal human osteoblasts.

AB - The NH2-terminal cleavage peptide of procalcitonin (N-proCT) recently was reported to be a bone cell mitogen (Burns DM et al., Proc Natl Acad Sci USA 86:9519-9523, 1989). We have investigated the effect of N-proCT on the proliferation of normal human cells that have the phenotype of mature osteoblasts (hOB cells). N-proCT treatment for 24, 48, or 96 h in concentrations from 1 nM to 1 μm did not significantly increase [3H]thymidine uptake (means ranged from -19% to 38% of control, no significant differences) in hOB cells (6-10 cell strains per experiment) plated at four different densities. However, the hOB cells responded significantly to treatment with transforming growth factor β (3 ng/ml), bovine insulin (300 μg/ml), or 30% fetal calf serum, which were included in all experiments as positive controls. The [3H]thymidine uptake data were confirmed in a direct cell count experiment tested at 96 h. Thus our data do not support the hypothesis that N-proCT is a potent mitogen for normal human osteoblasts.

UR - http://www.scopus.com/inward/record.url?scp=0025923066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025923066&partnerID=8YFLogxK

M3 - Article

C2 - 2068955

AN - SCOPUS:0025923066

VL - 6

SP - 489

EP - 493

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 5

ER -